We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
- Authors
Buzzonetti, Alexia; Fossati, Marco; Catzola, Valentina; Scambia, Giovanni; Fattorossi, Andrea; Battaglia, Alessandra
- Abstract
Purpose: To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab trial (NCT00418574). Methods: The study included 129 patients, 91 in the abagovomab arm and 38 in the placebo arm. Circulating CA125-specific cytotoxic T lymphocytes (CTL) were measured by a flow cytometry-based interferon-γ producing assay. Human antimouse antibody and anti-anti-idiotypic (Ab3) were assessed by ELISA. Patients were evaluated before starting the treatment and at different time points during induction and maintenance phases. Results: A similar percentage of patients in both the placebo and abagovomab arms had CA125-specific CTL (26.3 and 31.8 %, respectively; p = 0.673 by Fisher's exact test). Patients with CA125-specific CTL in both arms tended to have an increased relapse-free survival (RFS, log-rank test p = 0.095) compared to patients without. Patients ( n = 27) in the abagovomab arm without CA125-specific CTL but that developed Ab3 above the cutoff (defined as median Ab3 level at week 22) had a prolonged RFS compared to patients ( n = 24) that did not develop Ab3 above the cutoff (log-rank test p = 0.019). Conclusion: Abagovomab does not induce CA125-specific CTL. However, patients with CA125-specific CTL perform better than patients without, irrespective of abagovomab treatment. Abagovomab-induced Ab3 associate with prolonged RFS in patients without CA125-specific CTL. Further studies are needed to confirm these data and to assess the potential utility of these immunological findings as a tool for patient selection in clinical trial.
- Subjects
OVARIAN cancer treatment; OVARIAN cancer patients; IMMUNE response; CLINICAL trials; CYTOTOXIC T cells; MONOCLONAL antibodies; IMMUNOTHERAPY
- Publication
Cancer Immunology, Immunotherapy, 2014, Vol 63, Issue 10, p1037
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-014-1569-0